Slaoui spearheaded the overhaul of GlaxoSmithKline PLC pharmaceutical R&D and was instrumental in its DPU (discovery performance unit) initiative. Like Andrew Witty, Moncef Slaoui has spent the bulk of his career at GSK in a variety of roles spanning 28 years. (Also see " Witty Succumbs To Pressure: GSK Starts Formal Search For New CEO " - Scrip, 18 March, 2016.)
Prior to his current role as chairman of vaccines, where he oversaw the integration with the Novartis AG vaccines...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

